List of Peptide Therapies Companies in Pennsylvania - 10

Amyndas is a pharmaceutical company developing potent complement therapeutics for inflammatory diseases and disorders based on its patented technology for modulating the complement system.

Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.

Peptides

Helexva operates as a biotech company that specializes in treatment for fatal neurodegenerative diseases.

Longevity Biotech, Inc is a company that specializes in breakthrough peptide technology. They are focused on developing a new class of drug candidates called Hybridtides® that deliver unique product profiles. The company is currently in preclinical development.

Peptilogics was founded in 2013 to advance novel peptide therapeutics and harness the power of a design-based approach to drug discovery. Our approach bridges untapped chemical space to engineer peptides to treat some of the most challenging diseases. Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics through their computational platform.

Peroxitech is a privately held emerging biopharmaceutical company focused on the development and commercialization of a novel peptide for treating acute lung injury (ALI). The company has secured seed financing and Series A financing to advance its treatment for ALI, and has been awarded an NIH grant to develop a novel therapeutic approach to expand and improve the lung transplant organ pool.

SteroTherapeutics is pursuing novel drug therapies for orphan diseases, or diseases that are often life-threatening, and which affect fewer than 200,000.

At Verrica Pharmaceuticals, we are dedicated to easing the strain of hard-to-treat viral skin infections affecting millions of underserved patients. We are initially developing a topical therapy for the treatment of molluscum contagiosum, a highly contagious and primarily pediatric viral skin disease, and common warts. There is currently no FDA-approved treatment nor is there an established standard of care for either of these diseases, resulting in significant undertreated populations in two of the largest unmet needs in dermatology.

Windtree Therapeutics is a global, clinical-stage, biopharmaceutical and medical device company focused on the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. Windtree has four clinical and multiple pre-clinical programs spanning respiratory, cardiovascular and oncology disease states. The Company’s lead clinical programs include AEROSURF®, a novel med-device combination designed to deliver the company’s proprietary synthetic, peptide-containing surfactant non-invasively to premature infants with respiratory distress syndrome (RDS); istaroxime, a first-in-class, dual-acting agent being developed to improve cardiac function in patients with acute heart failure while avoiding the unwanted side effects of existing treatments; and rostfuroxin, a novel precision medicine targeting hypertensive patients with certain genetic profiles focused on the large and important resistant hypertension market. In all we do, we are driven by compassion and the aspiration to help patients and their families realize the hope they have for a life less impacted by disease.